arrow
M

Michihiko Shibata

school of medicine
H指数:14
被引数:870

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pretreatment geriatric nutritional risk index is associated with impaired treatment continuity and supportive care–relevant outcomes in unresectable pancreatic ductal adenocarcinoma

基线老年营养风险指数与不可切除胰腺导管腺癌患者治疗连续性受损及支持性护理相关结局相关

2026-08-120
PRE
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria

仑伐替尼联合经导管动脉化疗栓塞与阿替利珠单抗联合贝伐珠单抗作为超出“七限”标准的中间期肝细胞癌的一线治疗比较分析

2025-05-310
PRE
Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab

早期外周血淋巴细胞计数升高在预测接受度鲁瓦姆联合特瑞普利单抗治疗晚期肝细胞癌患者临床结局中的价值

CANCERS
IF4.4
2025-04-090
OA
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
2022-10-2231
OAAI
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019
2022-01-2726
OAAI